-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Blueberries Medical Q2 Revenue Grows 169%, What About Net Loss?
Blueberries Medical Q2 Revenue Grows 169%, What About Net Loss?
Blueberries Medical Corp. (OTCQB:BBRRF) (CSE:BBM) (FRA:1OA) released its financial results for the quarter ended on June 30, 2022, revealing total revenue of CA$39,826, an increase of CA$25,041 (or 169%) compared to Q2 2021.
Q2 2022 Financial Highlights
-
The gross profit, excluding the direct cost of production, in the extraction services is approximately 11%.
-
Gross profit was a loss of CA$75,475 compared to a loss of CA$88,021 in Q2 2021.
-
Net loss was CA$511,717 compared to net loss of CA$269,067 in Q2 2021
The company has pivoted its core business from cultivation to the extraction services, and identified a niche in export market of isolated products to the Latin America countries. To date, the company has been successful in exporting isolated products to Argentina. "Accordingly, in aligning with the company's strategy, the company has begun to expand its commercial revenues, adding more final products and services to others cannabis companies in Colombia and Latin America (Latam)," stated Facundo Garreton, CEO and chairman of Blueberries Medical Corp.
New Colombian Regulation
On February 18, 2022, the Colombian government issued the Resolution 227/2022 that improved license holders' conditions, such as extending from 5 to 10 years the term of the licenses and facilitating the process for applying to THC quotas. This resolution also regulated the use of non-psychoactive cannabis plant and its derivatives in food, beverages, alcoholic beverages, and dietary supplements. In this same direction, on April 1, 2022, the Colombian government issued the Resolution 539/2022 that regulates the Decree 811 of 2021 in all aspects related to the exportation of seeds for sowing, grain, plant component, cannabis plants, cannabis, cannabis derivatives and related products, allowing therefore the exportation of dry flower for medical and scientific purposes.
In anticipation to this regulatory chances, the company started in mid-2021 specific plans to:
-
Be ready to export premium grade THC with GACP CUMSC / IMC certification using a third-party cultivator model agreement with one of the largest flower processors in Colombia;
-
Started the development of multiple non-psychoactive high value-added ingredients for food and beverages, including specialties for chocolate and a fully translucid CBD water-soluble powder for beverages and other uses.
Blueberries expects that these new opportunities allowed by the updated regulation in Colombia will be rapidly traduced into sales and income for the company both locally and in development markets during the third quarter of 2022.
Results for the first two quarters of 2022 fall within the expectation of the management based on the strategic decision taken for the last quarter of 2021.
The company has begun to expand its commercial revenues, extending its business model to provide extraction services to other cannabis companies in Colombia. Together, with the anticipated increased revenue, the company will focus its spending on CAPEX and EUGMP certifications.
Photo: Benzinga; Sources: courtesy of Kindel Media via Pexels
Related News
Blueberries Provides Corporate Update, Extends Maturity Date Of Convertible Debentures
Blueberries Medical Reports Q1 2022 Financial Results, Eyes On Argentina's New Medicinal Market
Blueberries Medical Reports 110% Revenue Growth In 2021
Blueberries Medical Corp. (OTCQB:BBRRF) (CSE:BBM) (FRA:1OA) released its financial results for the quarter ended on June 30, 2022, revealing total revenue of CA$39,826, an increase of CA$25,041 (or 169%) compared to Q2 2021.
藍莓醫療公司(場外交易代碼:BBRRF)(CSE:BBM)(法蘭克福證券交易所股票代碼:1OA)發佈了截至2022年6月30日的季度財務業績,披露總收入39,826加元,與2021年第二季度相比增加了25,041加元(或169%)。
Q2 2022 Financial Highlights
2022年第二季度財務亮點
-
The gross profit, excluding the direct cost of production, in the extraction services is approximately 11%.
-
Gross profit was a loss of CA$75,475 compared to a loss of CA$88,021 in Q2 2021.
-
Net loss was CA$511,717 compared to net loss of CA$269,067 in Q2 2021
-
這個毛利,不包括直接生產成本,在採掘服務中大約是11%.
-
毛利是個損失75,475加元相比之下,2021年第二季度虧損88,021加元。
-
淨虧損為511,717加元2021年第二季度淨虧損269,067加元
The company has pivoted its core business from cultivation to the extraction services, and identified a niche in export market of isolated products to the Latin America countries. To date, the company has been successful in exporting isolated products to Argentina. "Accordingly, in aligning with the company's strategy, the company has begun to expand its commercial revenues, adding more final products and services to others cannabis companies in Colombia and Latin America (Latam)," stated Facundo Garreton, CEO and chairman of Blueberries Medical Corp.
該公司擁有將其核心業務從種植轉向採掘服務,並確定了向拉丁美洲國家出口孤立產品的利基市場。到目前為止,該公司已經成功地向阿根廷出口了孤立的產品。因此,為了與該公司的戰略保持一致,該公司已開始擴大其商業收入,為哥倫比亞和拉丁美洲(拉美)的其他大麻公司增加更多的最終產品和服務。法昆多·加勒頓,藍莓醫療公司首席執行官兼董事長。
New Colombian Regulation
哥倫比亞新法規
On February 18, 2022, the Colombian government issued the Resolution 227/2022 that improved license holders' conditions, such as extending from 5 to 10 years the term of the licenses and facilitating the process for applying to THC quotas. This resolution also regulated the use of non-psychoactive cannabis plant and its derivatives in food, beverages, alcoholic beverages, and dietary supplements. In this same direction, on April 1, 2022, the Colombian government issued the Resolution 539/2022 that regulates the Decree 811 of 2021 in all aspects related to the exportation of seeds for sowing, grain, plant component, cannabis plants, cannabis, cannabis derivatives and related products, allowing therefore the exportation of dry flower for medical and scientific purposes.
2022年2月18日,哥倫比亞政府發佈了第227/2022號決議,改善了許可證持有人的條件,如將許可證的有效期從5年延長到10年,並簡化了申請THC配額的過程。該決議還規範了非精神活性大麻植物及其衍生物在食品、飲料、酒精飲料和膳食補充劑中的使用。在同一方向上,哥倫比亞政府於2022年4月1日發佈了第539/2022號決議,該決議對2021年第811號法令進行了管理,該法令涉及用於播種的種子、穀物、植物成分、大麻植物、大麻、大麻衍生物及相關產品的出口,因此允許出口用於醫療和科學目的的乾花。
In anticipation to this regulatory chances, the company started in mid-2021 specific plans to:
在預見到這一監管機會後,該公司於2021年年中啟動了具體計劃,以:
-
Be ready to export premium grade THC with GACP CUMSC / IMC certification using a third-party cultivator model agreement with one of the largest flower processors in Colombia;
-
Started the development of multiple non-psychoactive high value-added ingredients for food and beverages, including specialties for chocolate and a fully translucid CBD water-soluble powder for beverages and other uses.
-
準備與哥倫比亞最大的花卉加工商之一簽訂第三方種植者示範協議,出口具有GACP CUMSC/IMC認證的優質THC;
-
開始開發多種食品和飲料的非精神活性高附加值配料,包括巧克力專用產品和用於飲料和其他用途的全透明CBD水溶性粉末。
Blueberries expects that these new opportunities allowed by the updated regulation in Colombia will be rapidly traduced into sales and income for the company both locally and in development markets during the third quarter of 2022.
藍莓預計,哥倫比亞最新法規允許的這些新機會將在2022年第三季度迅速轉化為公司在當地和發展市場的銷售和收入。
Results for the first two quarters of 2022 fall within the expectation of the management based on the strategic decision taken for the last quarter of 2021.
根據2021年最後一個季度的戰略決定,2022年前兩個季度的業績符合管理層的預期。
The company has begun to expand its commercial revenues, extending its business model to provide extraction services to other cannabis companies in Colombia. Together, with the anticipated increased revenue, the company will focus its spending on CAPEX and EUGMP certifications.
該公司已經開始擴大其商業收入,將其商業模式擴展到為哥倫比亞的其他大麻公司提供提取服務。與預期的收入增長一起,該公司將把重點放在CAPEX和EUGMP認證上。
Photo: Benzinga; Sources: courtesy of Kindel Media via Pexels
圖片來源:Pexels提供的Kindel Media
Related News
相關新聞
Blueberries Provides Corporate Update, Extends Maturity Date Of Convertible Debentures
藍莓提供公司動態,延長可轉換債券到期日
Blueberries Medical Reports Q1 2022 Financial Results, Eyes On Argentina's New Medicinal Market
藍莓醫療報告2022年第一季度財務業績,關注阿根廷新醫藥市場
Blueberries Medical Reports 110% Revenue Growth In 2021
藍莓醫療報告2021年收入增長110%
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧